Southwest Research Institute (SwRI) is collaborating with The University of Texas at San Antonio (UTSA) to explore and develop a novel platform or chemical process for synthesizing antibiotic ...

SwRI and UTSA will work together to combat the growing threat antimicrobial resistance poses to global health by developing a proof-of-concept platform to potentially create a whole library of new ...

The adaptive basket trial, which matches patients to treatments based on complex biomarker signatures, could help shape ...

The RESILIENCE clinical trial has been designed to explore the effectiveness and safety of remote ischemic conditioning (RIC) ...

Reveal Genomics' TNBCDX predicted response rates and risk of relapse for patients on anthracycline-free neoadjuvant therapy in a retrospective validation study.

Naomi Dempsey, MD, discussed developments in the HER2-positive breast cancer space, including personalized approaches, less ...

The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment ...

HOUSTON, TX / ACCESSWIRE / September 12, 2024 / (NASDAQ:CNSP)("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic ...

Adaptimmune received FDA approval for Tecelra, with a 39% response rate in synovial sarcoma. See why I rate ADAP stock as a ...

REVEAL GENOMICS® Unveils TNBCDX®: the First Genomic Test Designed for Early-stage Triple-Negative Breast Cancer ...

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be ...